-
公开(公告)号:EP4395807A2
公开(公告)日:2024-07-10
申请号:EP22865867.0
申请日:2022-09-06
CPC分类号: C07K14/71 , A61K38/47 , C12Y302/01031
-
公开(公告)号:EP4276200A3
公开(公告)日:2024-02-14
申请号:EP22194193.3
申请日:2013-07-24
摘要: The invention discloses oncogenic fusion proteins. The inventions provides methods for treating gene-fusion based cancers.
-
公开(公告)号:EP4308610A1
公开(公告)日:2024-01-24
申请号:EP22770612.4
申请日:2022-03-18
发明人: LIN, Shushan , LI, Yu , GAO, Xianglei , XIE, Can , YAN, Jiangyu , LIU, Liang , LI, Xiaoping , CHEN, Xiaofeng , LI, Wenjia
-
公开(公告)号:EP4265636A1
公开(公告)日:2023-10-25
申请号:EP22168872.4
申请日:2022-04-19
发明人: WIESBECK, Patrick , GIUMAN, Marco
摘要: The present invention relates to a fusion polypeptide comprising a purification domain; a cleavage domain; and a target peptide domain. The purification domain comprises 3 to 50 repeats of a nonapeptide, each nonapeptide independently having an amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 , whereby X 2 may be G, N or D, X 3 may be A, S, G, D, E, L or N, X 4 may be G or A, X 5 may be N, D, A or S, X 6 may be D or N, X 7 may be T, I, V or L, X 8 may be L, V, I, F or Y, and X 9 may be Y, I, V, F, T, N, D, K or S. The cleavage domain comprises an autoprotease or an amino acid sequence X a SX b X c X d X e X f X g , whereby X a is only optional and may be any amino acid, X b may be H, R, S, N, Y, G, K or Q, X c may be H, S or N, X d may be T, S, L, M, G, N, Q or W, X e is only optional may be S, P, A, T, L, R or D, X f is only optional and may be L, P, E, G, T, A, F or S, and X g is only optional and may be any amino acid. Further disclosed is a method for preparing a target peptide using the fusion polypeptide of the invention.
-
-
公开(公告)号:EP4208188A1
公开(公告)日:2023-07-12
申请号:EP21859105.5
申请日:2021-08-19
发明人: BOSS, Olivier , FREEMAN, Brian
-
公开(公告)号:EP4089106A1
公开(公告)日:2022-11-16
申请号:EP21923601.5
申请日:2021-11-04
申请人: Jiangnan University
发明人: ZHU, Shenglong , CHEN, Yongquan , WANG, Zhen
IPC分类号: C07K14/50 , C12N15/12 , A61K38/18 , A61P3/10 , A61P3/04 , A61P3/00 , A61P1/16 , A61P35/00 , A61P9/10 , A61P29/00
摘要: The disclosure discloses a new anti-metabolic disorder FGF analog and an application thereof, and belongs to the technical field of medicines. According to the disclosure, modification is performed based on an FGF19 mutant NGM282 to obtain a new FGF19 analog, which has the effects of being more long-acting and stable compared with NGM282, can better ameliorate liver impairment and correct diseases such as metabolic disorders, obesity, overweight, metabolic syndrome, diabetes and dyslipidemia and has no side effects of elevated cholesterol and dietary decline caused by the original FGF19 mutant NGM282 in a therapeutic process.
-
8.
公开(公告)号:EP4067374A1
公开(公告)日:2022-10-05
申请号:EP20894591.5
申请日:2020-11-16
发明人: LEE, Jung-Hyun , YIM, Hyung-Soon , AN, Young Jun , LEE, Kyeong Won , JEONG, Ye Eun , LEE, Won Kyu , WOO, Jurang , CHA, Kiweon
摘要: Provided is a polypeptide having FGF2 activity and improved temperature stability and protease resistance. The polypeptide includes at least one substitution selected from a substitution of aspartic acid (D) with glutamic acid (E) at position 28, a substitution of cysteine (C) with isoleucine (I) or leucine (L) at position 78, or a substitution of cysteine (C) with isoleucine (I) or tryptophan (W) at position 96 in SEQ ID NO: 1.
-
公开(公告)号:EP3412682B1
公开(公告)日:2022-08-31
申请号:EP18163799.2
申请日:2014-03-14
-
-
-
-
-
-
-
-
-